Using real-world data for post-market surveillance of drug safety After a therapeutic drug hits the market, it is crucial to continuously gather, analyze, and report data regarding its safety […] November 15, 2023 · Janssen Pharmaceutica
Beyond gluten-free: a hopeful future for those who suffer from Celiac disease Gluten-free dietary products contain more sugar and fats but fewer nutrients and are generally more expensive. A gluten-free diet can […] February 14, 2024 · SciMingo
Looking forward: Azalea Vision's smart lens is a game-changer for ocular disorders January 24, 2024 · BioVox
Belgian breakthrough in endometriosis research captures investors’ attention Even though endometriosis impacts millions of women globally, the condition remains poorly understood and researched, leading to delayed diagnosis and […] November 15, 2023 · BioVox
The rise of women’s health It’s been a Barbie world this summer with crowds of pink-clad moviegoers flooding the cinemas. Simultaneously, we’ve been witnessing a […] November 15, 2023 · V-Bio Ventures
Muna Therapeutics: hopeful solutions for memory loss Muna Therapeutics is developing transformative therapies for neurodegenerative diseases. These drugs aim to preserve cognition and enhance the brain’s resilience […] October 17, 2023 · V-Bio Ventures
Intelligent dentistry: AI is making surgeries safer The AIPLANT project aims to reduce complications from dental implant surgery using AI-based preoperative planning. The project is a collaboration […] October 17, 2023 · MEDVIA
V-Bio Ventures portfolio company Agomab raises $100 million Series C to advance fibrosis-focused pipeline — Round led by Fidelity Management & Research Company with participation from new investors EQT Life Sciences, Canaan and Dawn […] October 11, 2023 · V-Bio Ventures
V-Bio Ventures-funded Tanai Therapeutics develops first-in-class therapeutics for obesity Ghent, 6 December 2023 – VIB, Flanders’ leading life sciences institute, together with lead investor V-Bio Ventures has launched a […] December 6, 2023 · V-Bio Ventures
Azalea Vision Secures Prestigious European Innovation Council (EIC) Transition Grant Innovative Smart Contact Lens Developer Awarded €2.5M in Funding for Groundbreaking Ocular Health Technology Ghent, Belgium, March 12th, 2024 – […] March 12, 2024 · Press Release
Azalea Vision announces first on-eye test of ALMA, its revolutionary smart contact lens Promises New Hope for Patients with Vision Disorders Ghent, Belgium (December 4th, 2023) In a significant milestone, Azalea Vision, […] December 4, 2023 · Press Release
Hearts in space: a Belgian story of successful collaboration AstroCardia has developed a heart-on-a-chip to study cardiovascular aging… in space! Trials will begin in 2025 aboard the International Space […] September 26, 2023 · MEDVIA
V-Bio Ventures portfolio company Orionis Biosciences announces collaboration with Genentech to discover and develop molecular glue class medicines September 20, 2023, BOSTON, MA and GHENT, Belgium – Orionis Biosciences, a privately held life sciences company with an integrated […] September 20, 2023 · V-Bio Ventures
V-Bio Ventures portfolio company Corteria Pharmaceuticals raises EUR 65 million to advance its transformational medicines for cardiovascular diseases Ghent, Belgium, 7 September 2023 – Corteria Pharmaceuticals, a V-Bio Ventures portfolio company, is a biopharmaceutical company specialized in the […] September 7, 2023 · V-Bio Ventures
The obesity revolution: will new drugs bring about big changes? The recent approval of the obesity and diabetes drugs Wegovy, Ozempic, and Mounjaro has brought about big headlines, but are […] June 21, 2023 · V-Bio Ventures